In conclusion, higher elevated levels of serum biomarkers GFAP and UCH-L1 showed correlation with worse clinical outcomes at hospital discharge for AIS patients, regardless of whether they received endovascular treatment or not. Here, UCHL1 is linked to androgen insensitivity syndrome.